MedPath

MIP-1095 I-131

Generic Name
MIP-1095 I-131
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H25IN4O8
CAS Number
1258980-67-4
Unique Ingredient Identifier
7DM27RQ9V0
Background

MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News
pmc.ncbi.nlm.nih.gov
·

Meeting Report from the Prostate Cancer Foundation

The Prostate Cancer Foundation convened a meeting to discuss PSMA theranostics for prostate cancer, focusing on PSMA-targeted PET imaging and radionuclide therapy. Key topics included PSMA biology, clinical trials, patient selection, and combination therapies. The meeting aimed to advance the use of PSMA-targeted agents for imaging and treatment, highlighting the need for further research to optimize patient outcomes.

Related Clinical Trials:

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
PSMA-PET Guided Radiotherapy
FACBC Outcomes for Post Prostatectomy
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Phase III Radium 223 mCRPC-PEACE III
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy